Riskpilot← Back to searchSign inGet full accessDermaZip AB
ABActiveOrg 5569450140Rösundavägen 4All other professional, scientific and technical activities n.e.c. · NACE 7499Est. 20130 employees
Revenue 2024
SEK 0
EBITDA margin
—
+44% vs 2023
Equity ratio
52.1%
Financial strength
Net profit 2024
SEK -94K
+44% vs 2023
| Revenue | SEK 0 | — |
| EBITDA | SEK -94K | +44% |
| Net profit | SEK -94K | +44% |
| Total assets | SEK 96K | +45% |
| Equity | SEK 50K | -17% |
| Employees | 0 | — |
Legal name
DermaZip AB
Org number
5569450140
Legal form
Aktiebolag
NACE code
7499 · All other professional, scientific and technical activities n.e.c.
Founded
10 oktober 2013
Share capital
SEK 50 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Bolaget skall bedriva utvecklings- och konsultverksamhet inom medicinteknologi samt tillverkning och försäljning av medicin- teknisk utrustning, äga och förvalta fast och lös egendom, driva handel med aktier och värdepapper ävensom idka därmed förenlig verksamhet.
Address
Rösundavägen 4
Phone
+46706308562
Email
malin.wahlstrom@victoriakliniken.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Staff expenses | — | — | — | — | — | — | — | — | — | — |
| EBITDA | −40 | −419 | −57 | −104 | −36 | −55 | −170 | −103 | −168 | −94 |
| Depreciation & amort. | −0 | −2 187 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 |
| EBIT | −40 | −2 606 | −57 | −104 | −36 | −55 | −170 | −103 | −168 | −94 |
| Net financials | — | — | — | — | — | — | — | — | — | — |
| Profit before tax | −40 | −2 606 | −57 | −104 | −36 | −55 | −170 | −103 | −168 | −94 |
| Tax | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 |
| Net profit | −40 | −2 606 | −57 | −104 | −36 | −55 | −170 | −103 | −168 | −94 |
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 2 488 | 52 | 45 | 46 | 20 | 55 | 16 | 184 | 66 | 96 |
| Equity | 2 326 | 32 | −25 | −24 | −20 | 50 | −119 | 178 | 60 | 50 |
| Long-term debt | 0 | 0 | 66 | 66 | 36 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 162 | 20 | 3 | 3 | 3 | 5 | 136 | 6 | 6 | 46 |
| Total debt | 162 | 20 | 69 | 69 | 39 | 5 | 136 | 6 | 6 | 46 |
EBITDA margin
-9400000.0%
This company
15.8%
Market median
-59493771% vs market
20152024
Equity ratio
52.1%
This company
38.2%
Market median
+36% vs market
20152024
Return on equity
-188.0%
This company
18.4%
Market median
-1122% vs market
20152024
Net profit margin
-9400000.0%
This company
8.1%
Market median
-116049483% vs market
20152024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20152024
Debt / equity
0.92×
This company
0.62×
Market median
+48% vs market
20152024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Bolagsverket / SCB · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Bolagsverket / SCB · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Bolagsverket / SCB · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via Bolagsverket / SCB · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via Bolagsverket / SCB · Period 2015-01-01 – 2015-12-31
No data on file.
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Chairman | 2022 | — | — | |
| Deputy Board Member | 2022 | — | — | |
| Board of Directors | 2022 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Deifiera Sundsvall AB | Company | 60.0% | 60.0% | 2023 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Deifiera Sundsvall AB
DermaZip AB Board members of DermaZip AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Charles Max Rickard Randquist | Chairman | 0 companies |
| Yvette Susann Randquist | Deputy Board Member | 0 companies |
| Jon Henrik Falk | Board of Directors | 0 companies |